An evidence-based approach to the treatment of Graves' ophthalmopathy (Q33955231)

30 July 2017

1 reference

title

An evidence-based approach to the treatment of Graves' ophthalmopathy (English)

1 reference

30 July 2017

Wiersinga WM

1

1 reference

30 July 2017

Prummel MF

series ordinal

2

1 reference

30 July 2017

publication date

1 June 2000

1 reference

Endocrinology and Metabolism Clinics of North America

30 July 2017

published in

1 reference

30 July 2017

volume

29

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

297-319, vi-vii

1 reference

Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Cigarette smoking and treatment outcomes in Graves ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

The Incidence of Graves' Ophthalmopathy in Olmsted County, Minnesota

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Probable risk of tumor induction after retro-orbital irradiation for Graves' ophthalmopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Supervoltage orbital radiotherapy for Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Clever Is Not Enough: NOSPECS Is Form in Search of Function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

The initial clinical characteristics of Graves' orbitopathy vary with age and sex

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Radiation retinopathy after orbital irradiation for Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Lanreotide in the treatment of patients with thyroid eye disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Radiation retinopathy after standard radiotherapy for thyroid-related ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Graves ophthalmopathy: MR evaluation of 10-Gy versus 24-Gy irradiation combined with systemic corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Azathioprine in the treatment of thyroid-associated ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Natural history of thyroid associated ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Classification of eye changes of Graves' disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Effect of Abnormal Thyroid Function on the Severity of Graves' Ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Smoking and Risk of Graves' Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Acupuncture in the treatment of Graves' ophthalmopathy. A blinded randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Evidence based medicine: what it is and what it isn't

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Probable risk of tumour induction after retro-orbital irradiation for Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Treatment of Graves' disease and the course of ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Classification of the Eye Changes of Graves' Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Preventing Graves' ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

Retrospective evaluation of subtotal and total thyroidectomy in Graves' disease with and without endocrine ophthalmopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970133-X

7 January 2021

10.1016/S0889-8529(05)70133-X

Identifiers

DOI

1 reference

30 July 2017

1 reference